

Urological Cancer Therapeutics Drugs-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/UD9E52CD545MEN.html>

Date: April 2018

Pages: 132

Price: US\$ 3,480.00 (Single User License)

ID: UD9E52CD545MEN

Abstracts

Report Summary

Urological Cancer Therapeutics Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Therapeutics Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Urological Cancer Therapeutics Drugs 2013-2017, and development forecast 2018-2023

Main market players of Urological Cancer Therapeutics Drugs in United States, with company and product introduction, position in the Urological Cancer Therapeutics Drugs market

Market status and development trend of Urological Cancer Therapeutics Drugs by types and applications

Cost and profit status of Urological Cancer Therapeutics Drugs, and marketing status

Market growth drivers and challenges

The report segments the United States Urological Cancer Therapeutics Drugs market as:

United States Urological Cancer Therapeutics Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Urological Cancer Therapeutics Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Xofigo (radium Ra 223 dichloride)

Jevtana (cabazitaxel)

Inlyta (axitinib)

Votrient (pazopanib hydrochloride)

Sutent (sunitinib malate)

Zytiga (abiraterone acetate)

Xtandi (enzalutamide)

Opdivo (nivolumab)

Provenge (sipuleucel-T)

United States Urological Cancer Therapeutics Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Medical Research Laboratory

Others

United States Urological Cancer Therapeutics Drugs Market: Players Segment Analysis (Company and Product introduction, Urological Cancer Therapeutics Drugs Sales Volume, Revenue, Price and Gross Margin):

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER THERAPEUTICS DRUGS

- 1.1 Definition of Urological Cancer Therapeutics Drugs in This Report
- 1.2 Commercial Types of Urological Cancer Therapeutics Drugs
 - 1.2.1 Xofigo (radium Ra 223 dichloride)
 - 1.2.2 Jevtana (cabazitaxel)
 - 1.2.3 Inlyta (axitinib)
 - 1.2.4 Votrient (pazopanib hydrochloride)
 - 1.2.5 Sutent (sunitinib malate)
 - 1.2.6 Zytiga (abiraterone acetate)
 - 1.2.7 Xtandi (enzalutamide)
 - 1.2.8 Opdivo (nivolumab)
 - 1.2.9 Provenge (sipuleucel-T)
- 1.3 Downstream Application of Urological Cancer Therapeutics Drugs
 - 1.3.1 Hospital
 - 1.3.2 Medical Research Laboratory
 - 1.3.3 Others
- 1.4 Development History of Urological Cancer Therapeutics Drugs
- 1.5 Market Status and Trend of Urological Cancer Therapeutics Drugs 2013-2023
 - 1.5.1 United States Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Urological Cancer Therapeutics Drugs in United States 2013-2017
- 2.2 Consumption Market of Urological Cancer Therapeutics Drugs in United States by Regions
 - 2.2.1 Consumption Volume of Urological Cancer Therapeutics Drugs in United States by Regions
 - 2.2.2 Revenue of Urological Cancer Therapeutics Drugs in United States by Regions
- 2.3 Market Analysis of Urological Cancer Therapeutics Drugs in United States by Regions
 - 2.3.1 Market Analysis of Urological Cancer Therapeutics Drugs in New England 2013-2017
 - 2.3.2 Market Analysis of Urological Cancer Therapeutics Drugs in The Middle Atlantic

2013-2017

2.3.3 Market Analysis of Urological Cancer Therapeutics Drugs in The Midwest

2013-2017

2.3.4 Market Analysis of Urological Cancer Therapeutics Drugs in The West

2013-2017

2.3.5 Market Analysis of Urological Cancer Therapeutics Drugs in The South

2013-2017

2.3.6 Market Analysis of Urological Cancer Therapeutics Drugs in Southwest

2013-2017

2.4 Market Development Forecast of Urological Cancer Therapeutics Drugs in United States 2018-2023

2.4.1 Market Development Forecast of Urological Cancer Therapeutics Drugs in United States 2018-2023

2.4.2 Market Development Forecast of Urological Cancer Therapeutics Drugs by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Urological Cancer Therapeutics Drugs in United States by Types

3.1.2 Revenue of Urological Cancer Therapeutics Drugs in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Urological Cancer Therapeutics Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Urological Cancer Therapeutics Drugs in United States by Downstream Industry

4.2 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream

Industry in New England

4.2.2 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in The Midwest

4.2.4 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in The West

4.2.5 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in The South

4.2.6 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in Southwest

4.3 Market Forecast of Urological Cancer Therapeutics Drugs in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

5.1 United States Economy Situation and Trend Overview

5.2 Urological Cancer Therapeutics Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Urological Cancer Therapeutics Drugs in United States by Major Players

6.2 Revenue of Urological Cancer Therapeutics Drugs in United States by Major Players

6.3 Basic Information of Urological Cancer Therapeutics Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Urological Cancer Therapeutics Drugs Major Players

6.3.2 Employees and Revenue Level of Urological Cancer Therapeutics Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 UROLOGICAL CANCER THERAPEUTICS DRUGS MAJOR

MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Novartis

7.1.1 Company profile

7.1.2 Representative Urological Cancer Therapeutics Drugs Product

7.1.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Novartis

7.2 Pfizer

7.2.1 Company profile

7.2.2 Representative Urological Cancer Therapeutics Drugs Product

7.2.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Pfizer

7.3 Johnson & Johnson

7.3.1 Company profile

7.3.2 Representative Urological Cancer Therapeutics Drugs Product

7.3.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.4 AstraZeneca

7.4.1 Company profile

7.4.2 Representative Urological Cancer Therapeutics Drugs Product

7.4.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca

7.5 Astellas

7.5.1 Company profile

7.5.2 Representative Urological Cancer Therapeutics Drugs Product

7.5.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Astellas

7.6 Bristol-Myers Squibb

7.6.1 Company profile

7.6.2 Representative Urological Cancer Therapeutics Drugs Product

7.6.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

7.7 Abbott Laboratories

7.7.1 Company profile

7.7.2 Representative Urological Cancer Therapeutics Drugs Product

7.7.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

7.8 Celgene Corporation

7.8.1 Company profile

- 7.8.2 Representative Urological Cancer Therapeutics Drugs Product
- 7.8.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.9 Dendreon Corporation
 - 7.9.1 Company profile
 - 7.9.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.9.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
- 7.10 Ferring Pharmaceuticals
 - 7.10.1 Company profile
 - 7.10.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.10.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
- 7.11 GlaxoSmithKline plc
 - 7.11.1 Company profile
 - 7.11.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.11.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
- 7.12 Indevus Pharmaceuticals Inc
 - 7.12.1 Company profile
 - 7.12.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.12.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
- 7.13 Ipsen
 - 7.13.1 Company profile
 - 7.13.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.13.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ipsen
- 7.14 Roche Healthcare
 - 7.14.1 Company profile
 - 7.14.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.14.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
- 7.15 Sanofi S.A.
 - 7.15.1 Company profile
 - 7.15.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.15.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

- 8.1 Industry Chain of Urological Cancer Therapeutics Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

- 9.1 Cost Structure Analysis of Urological Cancer Therapeutics Drugs
- 9.2 Raw Materials Cost Analysis of Urological Cancer Therapeutics Drugs
- 9.3 Labor Cost Analysis of Urological Cancer Therapeutics Drugs
- 9.4 Manufacturing Expenses Analysis of Urological Cancer Therapeutics Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Urological Cancer Therapeutics Drugs-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/UD9E52CD545MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UD9E52CD545MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

